Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cg806
2. 1616428-23-9
3. Luxeptinib [usan]
4. Cg026806
5. Cg'806
6. Tq6pbx1ju0
7. Cg-026806
8. 1-[3-fluoro-4-[7-(5-methyl-1h-imidazol-2-yl)-1-oxo-2,3-dihydroisoindol-4-yl]phenyl]-3-(2,4,6-trifluorophenyl)urea
9. Urea, N-(4-(2,3-dihydro-7-(5-methyl-1h-imidazol-2-yl)-1-oxo-1h-isoindol-4-yl)-3-fluorophenyl)-n'-(2,4,6-trifluorophenyl)-
10. Urea, N-[4-[2,3-dihydro-7-(5-methyl-1h-imidazol-2-yl)-1-oxo-1h-isoindol-4-yl]-3-fluorophenyl]-n'-(2,4,6-trifluorophenyl)-
11. Luxeptinib [inn]
12. Unii-tq6pbx1ju0
13. Luxeptinib [who-dd]
14. Chembl4594420
15. Schembl17219212
16. Us9758508, Compound 7
17. Gtpl11671
18. Bdbm340031
19. Glxc-25679
20. Example 7 [us9758508b2]
21. Nsc791692
22. Nsc834160
23. Who 11799
24. Nsc-791692
25. Nsc-834160
26. Hy-139535
27. Cs-0204021
28. D96116
29. 1-{3-fluoro-4-[7-(5-methyl-1h-imidazol-2- Yl)-1-oxo-2,3-dihydro-1h-isoindol-4-yl]- Phenyl}-3-(2,4,6-trifluoro-phenyl)-urea
30. 3-{3-fluoro-4-[7-(4-methyl-1h-imidazol-2-yl)-1-oxo-2,3-dihydro-1h-isoindol-4-yl]phenyl-1-(2,4,6-trifluorophenyl)urea
31. 32,72,74,76-tetrafluoro-14-methyl-21,23-dihydro-11h-4,6-diaza-2(4,7)-isoindola- 1(2)-imidazola-3(1,4),7(1)-dibenzenaheptaphane-2,35-dione
| Molecular Weight | 495.4 g/mol |
|---|---|
| Molecular Formula | C25H17F4N5O2 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 495.13183745 g/mol |
| Monoisotopic Mass | 495.13183745 g/mol |
| Topological Polar Surface Area | 98.9 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 811 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Luxeptinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Luxeptinib, including repackagers and relabelers. The FDA regulates Luxeptinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Luxeptinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Luxeptinib supplier is an individual or a company that provides Luxeptinib active pharmaceutical ingredient (API) or Luxeptinib finished formulations upon request. The Luxeptinib suppliers may include Luxeptinib API manufacturers, exporters, distributors and traders.
Luxeptinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Luxeptinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Luxeptinib GMP manufacturer or Luxeptinib GMP API supplier for your needs.
A Luxeptinib CoA (Certificate of Analysis) is a formal document that attests to Luxeptinib's compliance with Luxeptinib specifications and serves as a tool for batch-level quality control.
Luxeptinib CoA mostly includes findings from lab analyses of a specific batch. For each Luxeptinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Luxeptinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Luxeptinib EP), Luxeptinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Luxeptinib USP).
LOOKING FOR A SUPPLIER?
